NDAORALTABLET, FOR SUSPENSION
Lifecycle
Pre-Launch
Clinical Trials
20
Data completeness
2/8 — Basic
NEVIRAPINE (nevirapine) by Cipla is non-nucleoside reverse transcriptase inhibitors [moa].
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection. It works by blocking the reverse transcriptase enzyme that HIV uses to replicate. This oral tablet/suspension formulation is a foundational antiretroviral therapy, particularly valuable in resource-limited settings and treatment-experienced patients.
Pre-Launch
Pre-launch stage suggests emerging commercial planning; team size and hiring will depend on market positioning strategy and geographic launch sequencing.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Started Sep 2014
11 enrolled
HIV Infections
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
Started Aug 2014
46 enrolled
HIV-1
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Started Apr 2014
150 enrolled
HIV
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease
HIV Infections
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
49 enrolled
HIV InfectionsPregnancy
Worked on NEVIRAPINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.